Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acusphere Imagify NDA is first for company, first for ultrasound cardiac imaging

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Acusphere's April 28 NDA for Imagify (perflubutane polymer microspheres for injectable suspension), the first new drug submission for the company, seeks approval of the polymer microsphere-encapsulated gas product as an ultrasound imaging agent to assess myocardial perfusion for the detection of coronary artery disease. If approved, Imagify would be the first ultrasound myocardial perfusion imaging agent. Acusphere believes Imagify "is also the first ultrasound imaging agent to demonstrate in large clinical trials clinically equivalent accuracy to nuclear stress testing." The NDA includes data from studies in more than 1,000 patients, including the two pivotal international multi-center Phase III Real-Time Assessment of Myocardial Perfusion clinical trials, RAMP-1 and RAMP-2. "Imagify is designed to provide real-time perfusion information with quicker results, lower cost, broader access and no exposure to radiation compared with nuclear stress tests," the company says. The agent is designed to work with currently available equipment and imaging techniques

You may also be interested in...



Keeping Track: US FDA's Rejection Of First RMAT BLA Blemishes Otherwise Positive Week Of Non-Oncology News

The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.

FDA Commissioner Nominee Hahn Advances To Full Senate, Despite Some Dems’ Reservations

Stephen Hahn, the Trump administration’s nominee to lead the US FDA, has been approved by the Senate Health, Education, Labor and Pensions (HELP) Committee, with some “no votes” from Democratic senators in leadership positions, and is expected to be considered by the full Senate this week.

FDA Holding February Public Meeting On Using AI In Radiology

The US agency will host a two-day meeting to discuss the evolution of artificial intelligence technology used to analyze radiological images when diagnosing patients and in advising radiologists to take optimal pictures. The takeaways from the meeting will be used by the FDA to help it develop its thinking on how to regulate such technology.

Topics

UsernamePublicRestriction

Register

PS003825

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel